A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases. The company’s foundational technology is based on the cutting-edge research…
Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in…
adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860,…
In our COVID world, we all need to get creative in building new ways to safely and effectively come together. The pandemic is showing us that Canada needs strong life sciences…
Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people…
Soundbite announces Health Canada Approval for SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SCS-P (14P) is intended for the treatment of patients suffering from peripheral…
FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment…
adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company…
© Copyright 2021. All rights reserved. Privacy Policy© Copyright 2021. Tous droits réservés. Politique de Confidentialité
